Song M, et al. - High-dose selenium has been shown to inhibit the development of carboplatin drug resistance in an ovarian cancer experimental model and may carry potentially serious toxicities in supranutritional doses. Consequently, researchers conducted a phase I trial of selenium/carboplatin/paclitaxel in combination to find out the maximum tolerated dose, safety, and effects of selenium on carboplatin pharmacokinetics in chemo-naive women with gynecologic cancers. To determine gene targets of selenium, correlative studies were also conducted. The maximum tolerated dose of selenium was not reached. Findings demonstrated safety as well as good tolerability of selenium added to carboplatin/paclitaxel chemotherapy. Also, carboplatin pharmacokinetics was not altered by the addition of selenium. Downregulation of RAD51AP1 may be seen with this treatment.